6392-97-8

Usage

Uses

Used in Organic Synthesis:
2-Phenyl-benzothiazol-6-ylamine is used as a building block in organic synthesis for the creation of various compounds with potential applications in different industries. Its unique structure allows for the formation of diverse chemical entities through reactions with other molecules.
Used in Pharmaceutical Research:
In pharmaceutical research, 2-Phenyl-benzothiazol-6-ylamine is utilized as a key component in the development of new drugs and therapeutic agents. Its structural and functional properties make it a promising candidate for the synthesis of bioactive molecules with potential medicinal uses.
Used as a Probe in Enzyme Kinetics Studies:
2-Phenyl-benzothiazol-6-ylamine serves as a valuable probe in studies of enzyme kinetics, providing insights into the mechanisms of enzyme-catalyzed reactions. Its interaction with enzymes can help researchers understand the factors influencing enzyme activity and selectivity.
Used as a Probe in Drug Receptor Interaction Studies:
2-Phenyl-benzothiazol-6-ylamine is also employed as a probe in investigations of drug-receptor interactions, aiding in the elucidation of the binding mechanisms and dynamics between drugs and their target receptors. This knowledge is crucial for the rational design of drugs with improved efficacy and selectivity.
Used in the Development of New Drugs and Therapeutic Agents:
Due to its structural and functional properties, 2-Phenyl-benzothiazol-6-ylamine may have potential applications in the development of new drugs and therapeutic agents. Its ability to form various bioactive compounds positions it as a valuable asset in the discovery and optimization of novel pharmaceuticals.

Upstream product

• 38338-23-7 6-nitro-2-phenyl-benzothiazole 
• 93930-09-7 thiosulfuric acid S-(2,5-diamino-phenyl ester) 
• 100-52-7 benzaldehyde 
• 2516-37-2 2-bromo-6-nitro-benzo[d]thiazole 
• 945400-80-6 2-bromanyl-1,3-benzothiazol-6-amine 
• 24388-23-6 2-phenyl-4,4,5,5-tetramethyl-1,3,2-dioxoborole 
• 6285-57-0 2-amino-6-nitrobenzothiazole 
• 2942-06-5 6-nitrobenzo[d]thiazole 
• 95-16-9 1,3-Benzothiazole 
• 533-30-2 1,3-benzothiazol-6-amine 
• 108-86-1 bromobenzene 
• 64-17-5 ethanol 
• 98-88-4 benzoyl chloride 
• 23451-98-1 2-amino-5-nitrobenzenethiol 

Downstream Products

• 863770-37-0 N-(2-phenylbenzothiazol-6-yl)acetamidine 
• 1426262-48-7 C₁₅H₁₁ClN₂OS 
• 1426262-52-3 C₂₈H₃₂N₄O₂S₂ 
• 1426262-55-6 C₂₈H₃₄N₄OS₂ 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of new benzoxazolone/benzothiazolone derivatives as multi-target agents against Alzheimer's disease

In this study, four series of compounds with benzoxazolone and benzothiazolone cores were designed, synthesized and evaluated as multifunctional agents against Alzheimer's disease (AD). Additionally, in order to shed light on the effect of the carbonyl groups of benzoxazolone/benzothiazolone, benzoxazole/benzothiazole-containing analogues were also synthesized and evaluated. Inhibition potency of all final compounds towards cholinesterase enzymes and their antioxidant activity were tested. Subsequently, the anti-inflammatory activity, cytotoxicity, apoptosis, and Aβ aggregation inhibition tests were also performed for selected compounds. The results indicated that compounds 11c, a pentanamide derivative with benzothiazolone core, and 14b, a keton derivative with benzothiazolone core, were considered as promising multi-functional agents for further investigation against AD. The reversibility, kinetic and molecular docking studies were also performed for the compounds with the highest AChE 14b (eeAChE IC50 = 0.34 μM, huAChE IC50 = 0.46 μM) and BChE 11c (eqBChE IC50 = 2.98 μM, huBChE IC50 = 2.56 μM) inhibitory activities.

Oxidative C-H Homocoupling of Push-Pull Benzothiazoles: An Atom-Economical Route to Highly Emissive Quadrupolar Arylamine-Functionalized 2,2′-Bibenzothiazoles with Enhanced Two-Photon Absorption

Copper(II)-catalyzed C-H/C-H coupling of dipolar 2-H-benzothiazoles end-capped with triphenylamine moieties affords highly fluorescent 2,2′-bibenzothiazoles with quadrupolar (D-π-A-π-D) architecture displaying large two-photon absorption (TPA) cross sections (543-1252 GM) in the near-infrared region. The notably higher TPA performance as compared to quadrupolar π-systems with a widely used 2,2′-bipyridine core, along with the ease of the synthesis and chelating N^N ability, makes the title biheteroaryl platform an attractive building block for a large scope of functional dyes exploiting nonlinear optical phenomena.

NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF

The present invention relates to novel hydrazone derivatives in which a terminal amine group is substituted with an aryl group or a heteroaryl group, and uses thereof.

Novel hydrazone derivatives comprising aryl or heteroaryl group substituted at terminal amine and use thereof

The present invention relates to novel hydrazone derivatives with an aryl or heteroaryl group substituted at a terminal amine group thereof and a use thereof.

Design, synthesis and structure-activity relationship of rhenium 2-arylbenzothiazoles as β-amyloid plaque binding agents

To continue our efforts toward the development of 99mTc PiB analogs, we have synthesized 24 neutral and lipophilic Re (as a surrogate of 99mTc) 2-arylbenzothiazoles, and explored their structure-activity relationship for binding to Aβ1-40 fibrils. These Re complexes were designed and synthesized via the integrated approach, so their 99mTc analogs would have a greater chance of crossing the blood-brain barrier. While the lipophilicities (log PC18 = 1.59-3.53) of these Re 2-arylbenzothiazoles were all within suitable range, their binding affinities (Ki = 30-617 nM) to Aβ1-40 fibrils varied widely depending on the selection and integration of the tetradentate chelator into the 2-phenylbenzothiazole pharmacophore. For potential clinical applications, further refinement to obtain Re 2-arylbenzothiazoles with better binding affinities (99mTc analogs for more widespread application via the use of SPECT scanners.

Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production

Heterocyclic amidines with anti-inflammatory and analgesic activity that inhibit nitrogen oxide production, of formula (I): in which:G1 and G2 are hydrogen, halogen, hydroxyl, C1-C4 alkoxy, C1-C4 alkyl, and an amidino substituent of formula Q, provided that, for each compound of formula (I), only one of the two substituents G1 or G2 is an amidino substituent of formula Q: and in which the substituents W, Y and X are combined to form 9- or 10-membered bicyclic heteroaromatic derivatives containing up to 2 hetero atoms in the same ring; andZ is an aryl or heteroaryl group, a linear or branched C1-C6 alkyl or alkenyl chain, a C1-C4 alkyl-aryl group or a C1-C4 alkyl-heteroaryl group.

Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production

Heterocyclic amidines with anti-inflammatory and analgesic activity that inhibit nitrogen oxide production, of formula (I): in which: G1 and G2 are hydrogen, halogen, hydroxyl, C1-C4 alkoxy, C1-C4 alkyl, and an amidino substituent of formula Q, provided that, for each compound of formula (I), only one of the two substituents G1 or G2 is an amidino substituent of formula Q: and in which the substituents W, Y and X are combined to form 9- or 10-membered bicyclic heteroaromatic derivatives containing up to 2 hetero atoms in the same ring; and Z is an aryl or heteroaryl group, a linear or branched C1-C6 alkyl or alkenyl chain, a C1-C4 alkyl-aryl group or a C1-C4 alkyl-heteroaryl group.